Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp (EMBC) is a global leader in diabetes care innovation, specializing in insulin delivery systems and digital health solutions for improved patient outcomes. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, product developments, and strategic initiatives.
Access comprehensive coverage of EMBC press releases, including quarterly earnings reports, regulatory milestones like FDA clearances, and partnerships advancing diabetes care technology. The page serves as a centralized resource for tracking the company’s progress in developing next-generation devices such as high-capacity patch pumps and integrated digital platforms.
Key updates include announcements on insulin delivery innovations, manufacturing expansions, and market penetration strategies. Content is organized to help users efficiently monitor Embecta’s position in the competitive medical devices sector while maintaining compliance with healthcare regulations.
Bookmark this page for direct access to verified Embecta Corp updates, ensuring you stay informed about critical developments affecting one of diabetes care’s most established medical technology providers.
Embecta Corp. (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced its upcoming fiscal third quarter 2024 financial results conference call. The event is scheduled for Friday, August 9, 2024, at 8:00 a.m. Eastern Time. During the call, the company will discuss financial results, provide an operational update, and host a Q&A session. Interested parties can access the live webcast through the provided link or via the company's investor relations website. A teleconference option is also available. For those unable to attend live, a webcast replay will be accessible from 11:00 a.m. ET on the same day and will remain archived on the website for one year.
Embecta presented two abstracts at the ADA's 84th Scientific Sessions, highlighting the potential benefits of a 300-unit insulin reservoir patch pump for adults with type 2 diabetes (T2D). Research indicated that the larger reservoir could reduce the need for frequent patch changes and better accommodate daily insulin needs. One study found that insulin total daily dose (TDD) was influenced by factors such as BMI and medication type. Another analysis showed that a 300u reservoir would meet the needs of 64% of T2D patients for 72-hour wear compared to 38% for a 200u reservoir. Embecta has submitted a 300u insulin delivery system to the FDA for approval.
Zimmer Biomet has announced the appointment of Devdatt Kurdikar to its Board of Directors, effective immediately. Kurdikar is currently the President, CEO, and a board member of Embecta, a leading diabetes management company. His extensive experience in the medical technology sector includes leadership roles at BD, Cardiac Science, Boston Scientific, and Baxter International. Zimmer Biomet's Chairman, Chris Begley, emphasized the value Kurdikar's expertise will bring as the company advances its strategic priorities. Kurdikar holds advanced degrees in Chemical Engineering and an MBA, and has a strong background in medtech innovation and leadership.
Embecta Corp. reported solid financial results for Q2 and the first half of fiscal year 2024, showcasing resilience in base business and strong operational execution. The company saw revenue growth, increased gross profit and margin, and positive adjusted net income. Strategic highlights include strengthening the base business and investing for growth with FDA review progress on insulin delivery systems.
Embecta Corp. (EMBC) announced a quarterly cash dividend of $0.15 per share for stockholders, payable on June 14, 2024. The dividend will be given to shareholders of record as of May 28, 2024.
Embecta Corp. (
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
